49 results on '"Schey, Stephen A."'
Search Results
2. Breakdown of Electric Vehicle Supply Equipment Installation Costs
3. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
4. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
5. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
6. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
7. sj-pdf-1-pmj-10.1177_0269216319833588 – Supplemental material for Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study
8. Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial
9. Micro Climate Assessment of Grid-Connected Electric Drive Vehicles and Charging Infrastructure. Final Report
10. Utilization Assessment of Target Electrification Vehicles at Marine Corps Base Camp Lejeune. Task 3
11. Implementation Approach for Electric Vehicles at Marine Corps Base Camp Lejeune. Task 4
12. Assessment of Charging Infrastructure for Plug-in Electric Vehicles at Marine Corps Base Camp Lejeune. Task 3
13. Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
14. Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min
15. The management of Castleman disease.
16. Idaho National Laboratory’s Analysis of ARRA-Funded Plug-in Electric Vehicle and Charging Infrastructure Projects: Final Report
17. Assessment of Fleet Inventory for Naval Air Station Whidbey Island. Task 1
18. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study: Final Report
19. Electric Vehicle Preparedness - Implementation Approach for Electric Vehicles at Naval Air Station Whidbey Island. Task 4
20. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for United States Coast Guard Headquarters
21. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for NASA Stennis Space Center
22. Electric Vehicle Preparedness: Task 2, Identification of Vehicles for Installation of Data Loggers for Marine Corps Base Camp Lejeune
23. Electric Vehicle Preparedness: Task 1, Assessment of Fleet Inventory for Marine Corps Base Camp Lejeune
24. Implementation Approach for Plug-in Electric Vehicles at Joint Base Lewis McChord. Task 4
25. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for National Institute of Health
26. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for the National Park Service: Sleeping Bear Dunes National Lakeshore
27. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for Department of Veterans Affairs – VA Manhattan Campus
28. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for NASA White Sands Test Facility
29. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for Department of Veterans Affairs. James J. Peters VA Medical Center, Bronx, NY
30. AVTA Federal Fleet PEV Readiness Data Logging and Characterization Study for NASA Glenn Research Center
31. Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study
32. Additional file 1: Figure S1. of The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
33. Myeloma Patient Outcome Scale
34. Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience
35. RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy
36. Quantifying the Burden of Multiple Myeloma Across Europe
37. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
38. Pomalidomide-An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma
39. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial
40. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
41. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
42. Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3
43. Lenalidomide-Based Treatment for Newly Diagnosed Multiple Myeloma Patients, Ineligible for Transplant: A Healthcare Cost-Impact Analysis in Europe
44. Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)
45. A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study
46. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)
47. Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
48. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).
49. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.